Surveillance of dalbavancin potency and spectrum in the United States (2012)

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 1, 2013, Pages 122-123

  Jones, Ronald N ^a   Flamm, Robert K ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; BACTERIAL INFECTION; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENOTYPE; HEALTH SURVEY; HUMAN; LETTER; PHENOTYPE; PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; HUMANS; TEICOPLANIN; UNITED STATES;

EID: 84876731996     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.01.003     Document Type: Letter

References (12)

1. Anderegg T.R., Biedenbach D.J., Jones R.N. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J Clin Microbiol 2003, 41:2795-2796.
2. Andes D., Craig W.A. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007, 51:1633-1642.
3. Biedenbach D.J., Bell J.M., Sader H.S., Turnidge J.D., Jones R.N. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother 2009, 53:1260-1263.
4. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2013, CLSI, Wayne, PA. ninth edition, M07-A9.
5. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
6. Dowell J.A., Goldstein B.P., Buckwalter M., Stogniew M., Damle B. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol 2008, 48:1063-1068.
7. Jones R.N., Fritsche T.R., Sader H.S., Goldstein B.P. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother 2005, 17:593-600.
8. Jones R.N., Sader H.S., Flamm R.K. Update of dalbavancin spectrum and potency in the USA; report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013, 75:304-307.
9. Jones R.N., Streit J.M., Fritsche T.R. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int J Antimicrob Agents 2004, 23:197-199.
10. Rennie R.P., Koeth L., Jones R.N., Fritsche T.R., Knapp C.C., Killian S.B., et al. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 2007, 45:3151-3154.
11. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
12. Zhanel G.G., Calic D., Schweizer F., Zelenitsky S., Adam H., Lagace-Wiens P.R., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010, 70:859-886.